ClinicalTrials.gg
RecruitingNCT07570823Updated Aug 13, 2026

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase 3 interventional study of SCTB35 injection and Rituxumab in DLBCL - Diffuse Large B Cell Lymphoma, sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

02

Conditions studied

  • DLBCL - Diffuse Large B Cell Lymphoma
03

In context

Lead sponsor

Sinocelltech Ltd. is the lead sponsor of 82 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years old
  • confirmed diffuse large B-cell lymphoma according to WHO 2022 criteria
  • (R/R) disease following at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
  • Participants who have failed after one are not candidates for high-dose chemotherapy followed by stem cell transplant (ASCT)
  • Presence of measurable or evaluable disease at baseline PS 0-2
  • ECOG PS 0-2
  • Adequate organ function and bone marrow function
  • Expected survival ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with antibodies targeting both CD20 and CD3
  • to rituximab, gemcitabine or oxaliplatin, or prior treatment with an anti-CD20 antibody in combination with the GemOx regimen
  • Peripheral neuropathy assessed to be Grade >1 according to National Cancer Institute (NCI CTCAE) v6.0 at enrollment
  • Known central nervous system (CNS) involvement by lymphoma
  • Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks
  • Treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to first SCTB35 administration
  • HSCT within 100 days prior to first SCTB35 administration, or any prior allogeneic HSCT or solid organ transplantation
  • Major surgery within 4 weeks prior to first SCTB35 administration
  • Chemotherapy and other non- antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration
  • Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (estimated)

Study arms

  • Experimental
    SCTB35-GemOx

    Drug: SCTB35 injection · Drug: Gemcitabine · Drug: Oxaliplatin

  • Active comparator
    R-GemOx

    Drug: Rituxumab · Drug: Gemcitabine · Drug: Oxaliplatin

Interventions

  • SCTB35 will be subcutaneously administered at a dose as specified

  • Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.

  • Participants will receive IV gemcitabine administration for up to 8 cycles.

  • Participants will receive IV oxaliplatin administration for up to 8 cycles.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Treatment-emergent adverse events/serious adverse events/adverse events of special interest

    Time frame: Up to approximately 3 years

  2. Progression free survival (PFS)

    Defined as the time from the date of randomization to the date of first documentation of progression disease (PD) or the date of death from any cause, whichever occurs first.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the duration from the date of randomization to the date of the participant's death.

    Time frame: Up to approximately 3 years

  2. Percentage of Participants Achieving Best Overall Response (BOR)

    BOR is defined as Complete Response (CR) or Partial Response (PR), determined by Lugano criteria

    Time frame: Up to approximately 3 years

  3. Percentage of Participants Achieving CR

    Percentage of participants who achieve a CR determined per Lugano criteria.

    Time frame: Up to approximately 3 years

  4. Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of response (CR or PR) to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 3 years

  5. Duration of Complete Response (DOCR)

    DOCR is defined as the time from the first occurrence of CR to disease progression or death, whichever occurs first.

    Time frame: Up to approximately 3 years

  6. Time to Response (TTR)

    Time to response is defined for participants achieving a CR/PR as the time from starting therapy to first a CR/PR.

    Time frame: Up to approximately 3 years

  7. Time to Complete Response (TTCR)

    Time to complete response is defined for participants achieving a CR as the time from starting therapy to first a CR.

    Time frame: Up to approximately 3 years

  8. Event-Free Survival (EFS)

    EFS is defined as the duration from randomization to disease progression determined by Lugano criteria as assessed by the investigator, initiation of any non-protocol-specified new anti-lymphoma therapy for any reason, or death (whichever occurs first).

    Time frame: Up to approximately 3 years

  9. Blood Concentrations of SCTB35

    The pharmacokinetics of SCTB35 will be analyzed based on the drug concentrations at respective timepoints in the blood samples (or blood derivative)

    Time frame: Up to approximately 1 years

  10. Anti-drug Antibodies of SCTB35

    Blood samples (or blood derivative) will be screened for antibodies binding to SCTB35

    Time frame: Up to approximately 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Nov 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Apr 2029
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570823
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jun 4, 2026
Primary completion
Nov 2027 (estimated)
Completion
Apr 2029 (estimated)
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SCTB35

Start the discussion